Over the past decade, a large body of observational evidence has suggested an association between lower vitamin D status (25-hydroxyvitamin D) and multiple acute and chronic disorders, including cancer, multiple sclerosis, depression and respiratory tract infections. This evidence has fostered the hypothesis that increasing vitamin D intake may treat and prevent such disorders. Our objective was to perform a critical analysis of the highestlevel evidence for ten common beliefs regarding vitamin D for the prevention of falls, fractures and respiratory tract infections, the reduction of cancer incidence/mortality and overall mortality, and the prevention or treatment of depression/mental well-being, rheumatoid arthritis and multiple sclerosis, as well as maximum dosing and regular testing. We searched the Cochrane Database of Systematic Reviews and PubMed (up to August 2014) for randomized controlled trials and systematic reviews/ meta-analyses based on those studies. All searches were performed, all evidence reviewed and each section written by at least two authors. The evidence shows that vitamin D supplementation provides some benefit in fracture prevention (likely ∼10-15 % relative reduction), particularly at a dose ≥800 IU and with calcium; a likely benefit in the rate of falls, though it is less clear whether the number of fallers changes; and a possible small (∼5 %) relative reduction in mortality. Evidence does not support the use of vitamin D supplementation for the prevention of cancer, respiratory infections or rheumatoid arthritis. Similarly, evidence does not support vitamin D supplementation for the treatment of multiple sclerosis and rheumatoid arthritis or for improving depression/mental well-being. Regular testing of 25-hydroxyvitamin D is generally not required, and mega-doses (≥300,000 IU) appear to increase harms. Much of the evidence is at high risk of bias, with multiple flaws, including analyses of secondary endpoints, small and underpowered studies, inconsistent results and numerous other issues. Therefore, enthusiasm for a vitamin D panacea should be tempered.
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elderly patients in long-term care. [2] [3] [4] As a result, investigators have postulated that vitamin D supplementation may reduce the risk of falling.
Systematic Review/Meta-Analysis
Eight meta-analyses [17] [18] [19] [20] [21] [22] [23] [24] of vitamin D levels and falls have been conducted, some with conflicting results. Online Table A provides an overview of these meta-analyses, including populations, outcomes and other methodological issues.
When considering this evidence, the analysis of Bfallsr ather than Bfallers^in many RCTs is a key issue. An analysis of Bfalls^means that people who fell more than once were counted more than once in the primary outcome analysis. These studies generally lacked the statistical power to detect a significant difference in the number of Bfallers^(people that fell one or more times). They relied, therefore, on repeat falls to obtain the desired number of total falls.
The most current systematic review included a trial sequential analysis 24 (a method to identify the ideal sample size of a meta-analysis and to potentially reduce false-positive results). It showed that the effect estimate for vitamin D, with or without calcium, lay within the futility boundary, i.e., that it did not alter the relative risk (RR) of falls by 15 % or more. Using a risk reduction threshold of 10 %, a sensitivity analysis (a method to assess the impact of key variables on a study's conclusions) found that the effect estimate also lay within the futility boundary.
Bottom Line
Vitamin D supplementation may reduce the number of falls among the elderly. There is also likely an overall reduction in the number of Bfallers^(a less biased outcome), although these results are less consistent.
BELIEF 2: VITAMIN D REDUCES FRACTURES

Observational Studies
For the most part, more recent observational studies are consistent with older studies that have established a relationship between low vitamin D levels and fractures. 5 A systematic review and meta-analysis of observational studies (17 case-control studies, n = 1903 hip fracture cases and 1953 controls) found 33 % lower vitamin D levels in cases compared to controls. This difference was significantly greater in studies with population-based versus hospital-based controls. 6 
Systematic Reviews/Meta-Analyses
There are many systematic reviews of vitamin D supplementation and fracture prevention. We focus on five large reviews published within the last 5 years with meta-analyses on fracture prevention (Table 1) .
Vitamin D alone did not appear to reduce hip, non-vertebral or total fractures. 25, 27, 28 When vitamin D was combined with calcium, the RR reductions were significant for total or nonvertebral fracture [25] [26] [27] [28] [29] and hip fractures, 25, 28 with two results non-significant for hip fractures. 26, 29 Two of the systematic reviews 26, 29 found that higher doses of vitamin D (>400 IU or a median dose of 800 IU) resulted in better and statistically significant RR reductions for nonvertebral and hip fractures. Although co-administration of calcium is important, it appears that doses <1000 mg are just as effective as higher doses. 26 The most recent of these included a trial sequential analysis 25 showing that the effect estimate for vitamin D, with or without calcium, was less than the futility boundary of 15 % RR reduction of total fractures. Furthermore, this effect is unlikely to be meaningfully changed by future studies. However, uncertainty remains around hip fracture, with more research needed to determine whether vitamin D with calcium results in a meaningful reduction in hip fractures (≥15 %).
Bottom Line
The best available evidence shows an apparent reduction in fractures associated with vitamin D when given at moderate doses (≥800 IU/day) together with calcium at low to moderate doses (perhaps 500 mg/day). The RR reductions are approximately 10-15 % for non-vertebral/total or hip fractures. At a 15 % baseline risk of any fracture, approximately 45-67 individuals would have to take vitamin D and calcium every day for 10 years to prevent one fracture.
BELIEF 3: VITAMIN D REDUCES RESPIRATORY TRACT INFECTIONS Observational Studies
A large cohort study (n = 18,883, age ≥12) suggested that upper respiratory tract infections (RTIs) are more common in people with low vitamin D levels and less common in those with high vitamin D levels.
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Systematic Reviews/Meta-Analyses
Three recent systematic reviews/meta-analyses [30] [31] [32] (Table 2) 32 meta-analysis was not without concern-for example, 75 % of the weighting was given to one of the seven trials. Overall, however, Mao 2013 32 was likely the most reliable analysis, and found that vitamin D had no effect in reducing RTIs.
In this case, it is probably more helpful to examine the individual RCTs. A Tools for Practice article (evidence synopsis) 35 summarized 11 RCTs. The RCT of highest quality and greatest application to western populations, Murdoch 2012, 36 found that vitamin D supplementation over two winters did not reduce cold or flu illness in 322 New Zealand university and/or health care workers. The majority of other trials, including a large trial of infants in Kabul Afghanistan, 37 did not find a reduction in respiratory infections. One trial of Mongolian children with profound vitamin D deficiency (17.5 nmol/L) found a reduction of 0.35 respiratory tract infections over 3 months. 38 
Bottom Line
Vitamin D supplementation does not prevent or reduce RTIs in western populations. There may be some benefit in children with profound vitamin D deficiency in developing countries, but this cannot be applied to all those countries.
BELIEF 4: VITAMIN D IMPROVES DEPRESSION AND MENTAL WELL-BEING Observational Studies
A systematic review and meta-analysis (n = 31,424) assessed observational data on the relationship between vitamin D and depression. The systematic review included one case-control study which found that patients with depression had lower vitamin D levels than did healthy controls. The mean difference between the groups was 17.5 nmol/L. Three cohort studies also included in the review explored the association between vitamin D levels and the risk of developing depression.
Results showed a significantly increased risk of depression in patients with low vitamin D levels (hazard ratio 2.21, 95 % CI 1.40-3.40). 8 
RCTs
Many of the RCTs on mental health and vitamin D are at high risk of bias, with poor randomization, lack of blinding, no description of patient characteristics, no intention-to-treat analysis and large loss to follow-up.
Online Table B includes 8 RCTs that used vitamin D supplementation to improve mental well-being or depression. [39] [40] [41] [42] [43] [44] [45] [46] Depression was not a requirement for inclusion in these studies. Based on low baseline depression scores, limited improvements in depression scales would be possible. None of the RCTs that included primarily patients without depression demonstrated a meaningful change in depression or mental well-being. Table 3 includes three RCTs of patients with depression or depressive symptoms. Mozaffair-Khosravi 2013 47 showed a statistically and clinically significant improvement in symptoms, but had several methodological flaws, including unclear randomization and allocation concealment, and no blinding or intention-to-treat analysis. Khoraminya 2012 49 also demonstrated a statistically and clinically significant improvement in symptoms. This trial was small and of short duration, and had methodological weaknesses. Yalamanchili 2012 48 found that vitamin D had no statistically significant effect on depression. Although this was a secondary analysis, there was no indication of a positive effect.
Systematic Reviews/Meta-Analyses
Three systematic reviews of RCTs on vitamin D supplementation and depression scores have recently been completed. [50] [51] [52] The conflicting results are shown in Table 4 . Vitamin D supplementation does not improve mental wellbeing scores in the general population without clear depression, even when 25-OHD levels are low. Vitamin D supplementation in patients with depression has conflicting, poorquality evidence and cannot be recommended.
BELIEF 5: VITAMIN D CAN PREVENT OR TREAT RHEUMATOID ARTHRITIS (RA) Observational Studies
In a prospective cohort study (n = 29,368) of women from Iowa (USA) aged 55-69 with no history of RA at baseline, 152 developed RA over 11 years of follow-up. When [56] [57] [58] Beck Depression Inventory in the 2 combined RCTs statistically significant but not clinically significant (estimated to be a 4-5-point change) 59 Weaknesses: Selective reporting of studies 45 and use of per-protocol analysis 44 * Standardized mean difference is a statistical measure used to combine different scales. It has limited clinical meaning, but it is generally agreed that differences smaller than 0.2 (or −0.2) are not clinically meaningful. 60 participants were divided into groups according to their vitamin D intake, those with the highest intake had a lower risk of developing RA than those with the lowest intake (RR 0.67, 95 % CI 0.44-1.00). In subgroups of vitamin D intake, both higher dietary (RR 0.72, 95 % CI 0.46-1.14) and supplemental vitamin D (RR 0.66, 95 % CI 0.43-1.00) were associated with lower risk. This study suggests a possible relationship between low vitamin D intake and increased risk of RA. 9 However, a larger cohort study (n = 186,389 women) failed to demonstrate a relationship between vitamin D intake and the incidence of RA or systemic lupus erythematosus. 10 
RCTs
Prevention. Participants enrolled in the Women's Health Initiative trial (n = 36,282, mean age 62) were randomized to a daily dose of 1000 mg calcium carbonate plus 400 IU vitamin D or placebo for an average of 5.1 years. In intention-to-treat analyses, there were no differences in RA incidence (RR 1.04, 95 % CI 0.76-1.41). 61 Treatment. We identified three small RCTs [62] [63] [64] in patients with RA (Table 5) , all with substantial issues with quality. One study 64 from Sweden, published over 40 years ago, reported that 31 % more patients on high-dose vitamin D (100,000 IU/ day) had clinical improvements at 1 year. The authors, however, provided no explanation regarding the specific subjective and objective outcomes measured. The Iranian study found no effect on Disease Activity Score or any other clinical outcome. 62 The Indian study found no difference in time to pain relief (their primary outcome), but reported that patients in the vitamin D arm had greater improvement in pain at 3 months on a visual analogue scale (VAS; median 50 vs. 30 % control group, p = 0.006). 63 The authors mistakenly tried to convert this continuous score difference to a number needed to treat.
Overall, given the inconsistent results and high risk of bias, there is no reliable evidence that vitamin D supplementation improves outcomes in RA.
Bottom Line
Vitamin D supplementation lacks consistent and reliable evidence in preventing or treating RA.
BELIEF 6: VITAMIN D CAN TREAT MULTIPLE SCLEROSIS (MS) Observational Studies
Observational studies have failed to demonstrate a consistent association between vitamin D levels and MS. 5 However, the association between increasing latitude and increasing prevalence of MS inevitably led some to hypothesize that lower exposure to ultraviolet radiation, and thereby lower vitamin D, at high latitudes contributes to or causes MS. 11 Furthermore, some observational studies have drawn associations between higher disease activity among MS patients and lower vitamin D levels.
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Systematic Reviews/Meta-Analyses
We could not identify any high-level evidence of vitamin D for the prevention of MS. Three systematic reviews/metaanalyses [65] [66] [67] have examined the effect of vitamin D on MS ( Table 6 ). The systematic reviews themselves have some methodological concerns. They included up to five of six possible trials. The six trials were small and had several methodological weaknesses. Among these, one found a positive change in MRI lesions and another found one positive clinical outcome out of seven. The one systematic review 66 that included a meta-analysis of the results found no effect on relapse rates in either the primary or sensitivity analyses.
Bottom Line
Although the present evidence base is poor, vitamin D supplementation does not appear to provide a clinical benefit in the treatment of MS.
BELIEF 7: VITAMIN D REDUCES MORTALITY Observational Studies
Multiple observational studies have found a positive association between low vitamin D levels and an increase in all-cause mortality.
14,15
We reviewed six of the systematic reviews/metaanalyses 16, 25, [69] [70] [71] [72] that examined the effect of vitamin D on mortality (Table 7) . Although these are large studies, mortality was a secondary outcome for almost all included trials. A wide range of patients (community-dwelling or institutionalized, with or without chronic medical conditions or previous fractures) and doses of vitamin D 2 or D 3 (with or without calcium) were included. Overall, the relative reduction in mortality ranged from 4 to 11 %. Some of the upper confidence intervals include no effect. This is not uncommon among meta-analyses, and an interpretation of benefit should not rely entirely on statistical significance testing with confidence intervals. 73 Based on these meta-analyses, the relative change in mortality may be a 2 % increase to a 13 % reduction, but is most likely around a 5 % reduction. Trial sequential analysis 25 suggests that optimum sample size of 130,005 participants has not been reached, indicating that the estimate could change with future studies. A number of the meta-analyses 16, 69 also found that while vitamin D 3 was effective, vitamin D 2 was ineffective. The results regarding the necessity of calcium co-administration are conflicting.
Although low 25-OHD levels have been associated with increased mortality in observational studies, it should be noted that emerging observational evidence indicates that high 25-OHD levels (>120 nmol/L) are also associated with increased mortality. 74 
Bottom Line
The effects of vitamin D on mortality are not consistently statistically significant. If real, the relative reductions in mortality are likely quite small (∼5 %).
BELIEF 8: VITAMIN D REDUCES CANCER INCIDENCE AND CANCER MORTALITY Observational Studies
There is relatively consistent evidence from observational studies of an association between lower vitamin D levels and an elevated risk of cancer. Pooled data from observational studies show a correlation between populations in the bottom versus top one third of circulating vitamin D levels and a 14 % RR increase of 1.14 (95 % CI 1.01-1.29; 5003 events) in death from cancer.
16 
RCTs
A frequently cited RCT (n = 1179 white women over age 55) 75 demonstrated that supplementation with vitamin D plus calcium resulted in RR of developing cancer of 0.402 (P = 0.01) compared to placebo. The trial, however, had many limitations: industry-funded, secondary analysis of fracture trial, unclear allocation concealment, small number of events reported, efficacy of blinding not described, and outcome was patient reporting of new onset cancers.
Systematic Reviews/Meta-Analyses
Early systematic reviews 27, 76, 77 included limited numbers of RCTs and did not perform meta-analyses. Generally, these reviews included the RCT 75 mentioned above and nonstatistically significant RCTs to conclude that possible clinically important effects could not be ruled out.
Two meta-analyses (7 trials, n = 48,167; 18 trials, n = 50,623) 25, 78 have been performed more recently. Both reported that vitamin D supplementation did not alter the incidence of cancer: RR 0.99 (95 % CI 0.93-1.05), 25 and RR 1.00 (95 % CI 0.94-1.06). 78 Trial sequential analysis conducted in both metaanalyses found that the effect of vitamin D supplementation on the incidence of cancer lay within the futility boundary (15 % RR reduction), and no further studies were required. 25, 78 The larger meta-analysis 78 also assessed the effect of vitamin D supplementation on cancer mortality and found a statistically significant benefit, RR 0.88 (95 % CI 0.78- 
Bottom Line
Vitamin D supplementation does not reduce the incidence of cancer. The impact of vitamin D supplementation on cancer mortality is less clear and has been assessed only by lowquality evidence.
BELIEF 9: VITAMIN D DOSE-MORE IS BETTER RCTs
Two large RCTs (Table 8 ) provide concerning evidence that higher doses of vitamin D could increase the risk of falls and fracture. 79, 80 Given the present enthusiasm for vitamin D supplementation and the pervasive belief that more is better, these trials serve as a good reminder. Even in the two clinical areas of best evidence for vitamin D supplementation (falls and fracture prevention), massive doses can increase the very outcomes we are trying to prevent. Additionally, there is some evidence (albeit observational) that higher 25-OHD levels (>120 nmol/L) are associated with increased mortality. 74 
Bottom Line
High-dose vitamin D has been shown to increase the risk of falls and fractures. Single high-dose (≥300,000 IU) supplementation should not be recommended. even when repeating the test in the same person at the same time. 5 Therefore, changes in levels may not be discernable in individuals at doses of 800 IU/day, as this dose on average changes the serum vitamin D about as much as the variance in assay. 81 Enrollment in many vitamin D supplementation trials was not based on 25-OHD levels, and treatment of patients without screening 25-OHD level was found to be beneficial. 29, 72, 82 Finally, routine screening/testing of 25-OHD levels is an onerous and costly exercise. The cost of a 25-OHD assay is $61.32, 81 two to three times the cost of a year's worth of vitamin D.
Despite recommendations to the contrary, testing 25-OHD levels has become widespread in recent years. One consequence has been confusion regarding the 25-OHD level indicative of deficiency. The Bcut-points^for deficiency and sufficiency used by laboratories are neither standardized nor based on rigorous scientific studies. The number of people with vitamin D insufficiency/deficiency may be overestimated, because many labs use higher cut-points than are indicated by the evidence. 
Vitamin D supplementation in the general adult population is safe, and supplementation without testing is reasonable. Testing may be appropriate when clinically indicated (e.g., 
CONCLUSION
Severe vitamin D deficiency causes important health problems (e.g., rickets). Additionally, lower 25-OHD levels have sometimes been associated with a long list of medical conditions and negative outcomes. However, association is not causation, and high-quality, high-level evidence for supplementation is frequently lacking. Vitamin D may prove to be a good surrogate for general well-being.
At the present time, evidence supports vitamin D supplementation to help prevent fractures (particularly if given with calcium), and possibly to prevent falls and slightly reduce mortality (particularly in older patients [>70 years of age]). No other effects are proven. For many other conditions, the evidence for vitamin D supplementation is plagued by the use of small, poor-quality trials. Lastly, testing of 25-OHD levels in the general population is not necessary, and very high doses should be avoided.
